Cinclus Pharma: EUR28m financing agreement - Redeye

Redeye leaves a comment following Cinclus’ announcement that it has secured a structured growth-debt financing facility of up to EUR28m from Claret Capital Partners. The funding strengthens the company’s financial flexibility as it advances linaprazan glurate through late-stage development and prepares for the second part of its phase III program. We view the agreement as a constructive step that improves Cinclus’ strategic optionality ahead of its upcoming clinical milestones and potential partnering discussions.

Länk till analysen i sin helhet: https://www.redeye.se/research/1156867/cinclus-pharma-eur28m-financing-agreement?utm_source=finwire&utm_medium=RSS